275 filings
8-K
CPRX
Catalyst Pharmaceuticals Inc
8 May 24
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
4:54pm
8-K
CPRX
Catalyst Pharmaceuticals Inc
13 Mar 24
Available in the U.S. by Prescription for Patients Aged Two Years and Older
5:01pm
8-K
CPRX
Catalyst Pharmaceuticals Inc
28 Feb 24
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
8:37pm
8-K
CPRX
Catalyst Pharmaceuticals Inc
21 Feb 24
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD
4:34pm
8-K
CPRX
Catalyst Pharmaceuticals Inc
9 Jan 24
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock
5:15pm
8-K
16mef41e8y7kc
8 Jan 24
Regulation FD Disclosure
8:10am
8-K
qku3a27azpw6e 13eh
5 Jan 24
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
5:23pm
8-K
36nq pc2cypp
19 Dec 23
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
4:30pm
8-K
cq9k8x58
7 Dec 23
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
4:30pm
8-K
415c729a0bn7
8 Nov 23
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
4:35pm
8-K
ctt8j6 gcw5
3 Nov 23
New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio
4:30pm
8-K
1uwl0ggkfx kdvtmqirz
27 Oct 23
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
4:30pm
8-K
ye8ua8y65
20 Oct 23
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
4:31pm
8-K
56joj
13 Oct 23
The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome
8:15am
8-K
z6upmd
25 Sep 23
Regulation FD Disclosure
5:46pm
8-K
cwcaf5kxzbb uq54ns
25 Aug 23
Departure of Directors or Certain Officers
4:31pm
8-K
euc u9xxga1bsb
9 Aug 23
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
4:34pm
8-K
9c3uc4fmcuedlhr
28 Jul 23
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
4:30pm
8-K
rrumk3fva t4i
21 Jul 23
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
4:30pm
8-K
dujs 8i1pm9aogjsrq
23 Jun 23
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
4:31pm